About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may ...

Company Overview - Bicara Therapeutics focuses on bifunctional antibodies that target tumors, with its lead program being an EGFR TGF-beta agent designed to deliver TGF-beta to the tumor microenvironment [2][3] - The company was founded in 2020 and licensed intellectual property from Biocon, continuing development over the past four to five years [3] Clinical Development - Bicara Therapeutics has initiated a registrational trial for its lead program in the recurrent metastatic head and neck cancer setting, which began early last year [3] - The company expects to have top-line data from this trial by mid-2027 [3]

Summary of Bicara Therapeutics FY Conference Call Company Overview - Bicara Therapeutics focuses on bifunctional antibodies targeting tumors, specifically utilizing an EGFR TGF-beta mechanism to enhance treatment efficacy in cancer patients [1][2] - The company was founded in 2020 and licensed intellectual property from Biocon [1] Key Developments - Bicara has initiated a registrational trial for its lead program in recurrent metastatic head and neck cancer, with top-line data expected in mid-2027 [2] - The trial targets an HPV-negative population, historically considered immune excluded, where effective drug delivery has been challenging [5] Mechanism of Action - The synergy between EGFR and TGF-beta is emphasized, with higher levels of both proteins present in HPV-negative head and neck cancer patients [6] - TGF-beta is believed to help overcome acquired resistance mechanisms associated with EGFR, enhancing treatment effectiveness [8][12] Clinical Data - Early data presented at ASCO 2023 showed a 21% complete response rate at the 1500 mg dose, significantly higher than the historical 4%-7% complete response rate for Pembrolizumab (Pembro) [9][10] - The confirmed response rate in the same population was reported at 55%, with a median duration of response of 21.7 months [11] - The trial demonstrated deeper and more durable responses compared to existing therapies, indicating the potential of TGF-beta in enhancing treatment outcomes [12] Trial Design and Regulatory Strategy - The ongoing phase 3 trial is designed as a three-arm study, comparing ficerafusp alfa at two doses against Pembro monotherapy [40][42] - The trial aims for accelerated approval based on overall response rate (ORR) and will continue to follow patients for overall survival (OS) [44] - Approximately 600-650 patients will be enrolled, with a focus on ensuring a high degree of confidence in meeting the OS endpoint [52] Commercial Strategy - Bicara raised $172 million to build its commercial and medical affairs infrastructure, targeting a launch in the U.S. [74][76] - The company plans to leverage its understanding of the prescriber universe in head and neck cancer, which is relatively concentrated [76] Future Opportunities - Bicara is exploring additional indications for ficerafusp alfa beyond head and neck cancers, including colorectal cancer and locally advanced settings where TGF-beta levels are increased due to radiation [81][83] - The company is also developing a PCR HPV test for co-approval, which is expected to facilitate patient enrollment and reimbursement processes [71][73] Conclusion - Bicara Therapeutics is positioned to make significant advancements in the treatment of head and neck cancer through its innovative approach combining EGFR and TGF-beta mechanisms, with promising clinical data and a strategic plan for commercialization and further research into additional cancer types [1][2][81]

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on March 2, 2026 to one new employee under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employee received a non-qualified stock option to purchase 115,000 shares of Bicara’s common stock, par value $0.0001 per share, w ...

Bicara Therapeutics (NasdaqGM:BCAX) FY Conference March 02, 2026 01:10 PM ET Company ParticipantsRyan Cohlhepp - President and COOConference Call ParticipantsTyler Van Buren - Senior Research AnalystTyler Van BurenRight. good afternoon everyone. Tyler Van Buren here, Senior Research Analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th annual health care conference. For our next session, we have a hybrid presentation and fireside chat style Q&A with Bicara, and it's my pleasure to introduce R ...

Exhibit 1.1 BICARA THERAPEUTICS INC. 7,175,000 SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE UP TO 2,200,000 SHARES OF COMMON STOCK UNDERWRITING AGREEMENT c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 February 24, 2026 Morgan Stanley & Co. LLC TD Securities (USA) LLC BofA Securities, Inc. As Representatives of the several Underwriters c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 c/o BofA Securities, Inc. One Bryant Park ...

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of its underwritten public offering of 8,581,250 shares of its common stock, and to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of its common stock at an exercise price of $0.0001 per share. The shares of common stock sold inclu ...

Core Viewpoint - Bicara Therapeutics provided an update on their clinical data related to head and neck cancer during a conference call, coinciding with a presentation at the 2026 Multidisciplinary Head and Neck Cancer Symposium [2]. Group 1: Company Overview - Bicara Therapeutics is focused on developing innovative therapies for cancer treatment, specifically in the area of head and neck cancer [2]. - The company’s Chief Corporate Affairs Officer, Jenna Cohen, led the conference call to discuss recent developments and data [2]. Group 2: Clinical Data Presentation - The data presented by Dr. Dan Zandberg from the UPMC Hillman Cancer Center was highlighted in a press release issued by the company [2]. - The press release and accompanying slides are available on the company's website for investors [2].

Core Viewpoint - Bicara Therapeutics Inc. has announced a public offering of 7,175,000 shares at $16.00 per share, aiming to raise approximately $150 million to support its clinical and commercial initiatives for ficerafusp alfa, a bifunctional therapy for solid tumors [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants for 2,200,000 shares at a price of $15.9999 each, with gross proceeds expected to be around $150 million before expenses [1]. - The offering is set to close on or about February 26, 2026, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 1,406,250 additional shares at the public offering price [1]. Group 2: Use of Proceeds - Net proceeds will be used to enhance medical and commercial infrastructure for a planned regulatory filing and launch of ficerafusp alfa in the U.S. [2]. - Funds will also support the development of ficerafusp alfa in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including a less frequent dosing schedule [2]. - Additional uses include covering manufacturing costs for ongoing drug development and early signal-finding for future indication expansion [2]. Group 3: Company Overview - Bicara Therapeutics is focused on developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, designed to penetrate tumors by overcoming barriers in the tumor microenvironment [6]. - Ficerafusp alfa combines an EGFR-directed monoclonal antibody with a domain that binds to TGF-β, aiming to reverse the fibrotic and immune-excluded tumor microenvironment [6]. - The therapy is being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [6].